文献速递类风湿关节炎

接受达标治疗管理的早期类风湿关节炎患者五年心血管事件风险:一项病例对照研究

Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究探讨达标治疗(T2T)抑制炎症能否改善类风湿关节炎(RA)中过高的心血管疾病风险。比较接受T2T管理的早期RA患者与心血管危险因素匹配的非RA人群及历史RA队列的5年心血管事件发生率。早期RA队列心血管事件发生率与匹配对照相似(HR 0.53,95%CI 0.15,1.79),未出现超额心血管事件。

要点

  • 早期RA接受T2T管理5年,心血管事件发生率与心血管危险因素匹配的非RA对照相似(HR 0.53,95%CI 0.15,1.79)。
  • 历史RA队列心血管事件发生率显著高于其匹配对照(HR 1.9,95%CI 1.16,3.13)。
  • 早期RA队列心血管事件发生率显著低于历史RA队列,校正炎症、甲氨蝶呤使用及传统心血管危险因素后差异变得不显著。

核心结论

  • 接受T2T策略管理的早期RA患者在5年内与心血管危险因素匹配的对照相比未出现超额心血管事件。

研究设计与样本

  • 本研究为观察性研究,使用全市医院数据和早期RA注册登记。
  • 早期RA患者接受T2T管理,历史RA患者接受常规诊疗。
  • 每例早期RA或历史RA患者按年龄、性别和心血管危险因素与3名非RA对照匹配。
  • 排除使用抗血小板或抗凝药物、已有心血管疾病、慢性肾脏病或其他自身免疫病的患者。
  • 所有受试者随访至多5年,主要终点为首次发生心血管事件。

主要发现

  • 早期RA队列(n=261)与早期RA对照的心血管事件发生率相似,风险比为0.53(95%CI 0.15,1.79)。
  • 历史RA队列(n=268)的心血管事件发生率显著高于历史RA对照,风险比为1.9(95%CI 1.16,3.13)。
  • 早期RA队列心血管事件发生率显著低于历史RA队列,校正炎症、甲氨蝶呤使用和传统心血管危险因素后差异变得不显著。

关键数值与推荐

  • 早期RA队列与匹配对照比较心血管事件的风险比为0.53(95%CI 0.15,1.79)。
  • 历史RA队列与匹配对照比较心血管事件的风险比为1.9(95%CI 1.16,3.13)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study explored whether the excess cardiovascular (CV) disease (CVD) risk in RA could be ameliorated by suppression of inflammation using a treat-to-target (T2T) approach. We compared the CV event (CVE) incidence among ERA patients managed by a T2T strategy with a CV risk factor-matched non-RA population and a historical RA cohort (HRA). METHODS: This was an observational study using the city-wide hospital data and the ERA registry. ERA patients received T2T management while HRA patients received routine care. Each ERA/HRA patient was matched to three non-RA controls according to age, gender and CV risk factors. Patients on antiplatelet/anticoagulant agents, with pre-existing CVD, chronic kidney disease or other autoimmune diseases were excluded. All subjects were followed for up to 5 years. The primary end point was the first occurrence of a CVE. RESULTS: The incidence of CVE in the ERA cohort (n = 261) and ERA controls were similar with a hazard ratio of 0.53 (95% CI 0.15, 1.79). In contrast, the incidence of CVE in the HRA cohort (n = 268) was significantly higher than that of the HRA controls with a hazard ratio of 1.9 (95% CI 1.16, 3.13). The incidence of CVE in the ERA cohort was significantly lower than that of the HRA cohort and the difference became insignificant after adjusting for inflammation, the use of methotrexate and traditional CV risk factors. CONCLUSION: ERA patients managed by a T2T strategy did not develop excess CVE compared with CV risk factor-matched controls over 5 years.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lam TO, Cheng IT, Lam SH, et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study. Rheumatology (Oxford). 2023. PMID: 36707997. doi:10.1093/rheumatology/kead039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。